Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hillard Lazarus

Hematology & Oncology Cleveland, OH Medical Doctor

NPI 1255351920 CMS profile 911116

11100 Euclid Ave, Cleveland, OH 44106

Open in the dashboard

General payments

$2,044,800

639 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hillard Lazarus of Cleveland, OH is reported in the CMS Open Payments database as having received $2,044,800 across 639 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $103,113 23
2024 General $321,610 80
2023 General $363,016 66
2022 General $375,338 90
2021 General $366,498 42
2020 General $281,060 85
2019 General $234,165 253

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hillard Lazarus
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Hillard Lazarus were reported at $103,113. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Hillard Lazarus Hematology & Oncology median Middle half National median
2019 $234,165 $529 $121–$2,516 $163
2020 $281,060 $339 $82–$2,213 $114
2021 $366,498 $263 $49–$1,965 $132
2022 $375,338 $416 $103–$2,395 $149
2023 $363,016 $542 $125–$2,646 $160
2024 $321,610 $692 $141–$3,008 $164
2025 $103,113 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Partner Therapeutics, Inc. $1,416,870 83 payments
  2. Seattle Genetics, Inc. $179,941 177 payments
  3. Jazz Pharmaceuticals Inc. $157,219 130 payments
  4. E.R. Squibb & Sons, L.L.C. $72,997 60 payments
  5. Celgene Corporation $43,148 17 payments
  6. Amgen Inc. $41,200 50 payments
  7. AstraZeneca Pharmaceuticals LP $35,076 37 payments
  8. CSL Behring $23,785 12 payments
  9. Pfizer Inc. $18,639 19 payments
  10. Teva Pharmaceuticals USA, Inc. $17,220 9 payments
  11. Other $38,704 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,493,248 96 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $471,209 153 payments
  3. Travel and Lodging $69,449 215 payments
  4. Food and Beverage $10,795 174 payments
  5. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. LEUKINE Hematology/Oncology $1,224,149 71 payments
  2. ADCETRIS $197,192 192 payments
  3. Leukine Hematology $192,721 12 payments
  4. EMPLICITI $57,104 54 payments
  5. VYXEOS Oncology $43,675 45 payments
  6. Blincyto $38,456 49 payments
  7. DEFITELIO $37,533 29 payments
  8. CALQUENCE $35,076 37 payments
  9. VYXEOS Hematology/Oncology $32,094 15 payments
  10. VYXEOS Hematology/Oncology $28,518 19 payments
  11. Other $110,093 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

639 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record